- Geron discontinues Phase 3 IMpactMF trial evaluating imetelstat in relapsed/refractory myelofibrosis
- Independent DMC advised the study was unlikely to meet its primary overall survival endpoint
- Removes key pipeline expansion opportunity for lead drug Rytelo
?? Negative AI Sentiment (-8.5 / 10)